CML Flashcards

1
Q
Name the second generation TKI that is associated with the side effect (can only use each one)
Hyperglycemia -
Pleural effusions and pulm HTN -
Voluminous Diarrhea  -
Cardiac infarct-
A

Hyperglycemia - Nilotinib
Pleural effusions - Dasatinib
Voluminous Diarrhea - Bosutinib (also causes thrombocytopenia, elevated LFTs)
Cardiac infarct Nilotinib, (3rd gen: Ponatinib)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

In clinical trials of Imatinib stoppage (STIM, TWISTER) what TWO patient features were inclusion criteria for entering the study?

A
  1. Patients treated with imatinib x 3 + years ( 5 data points for BCR-ABL transcript)
  2. Undetectable MRD (MMR log 5 in stim, 4.5 twister) x 2 years
    (STIM: CP and AP, TWISTER: CP only)

What percentage of individuals will have durable remission upon stoppage of Imatinib?
▪ 40-50%

o What clinical feature was most predictive of patients who could successfully come off therapy?
▪ Low sokal (Sokal- blast age plt spleen size)
▪ Longer duration of imatinib therapy (>50 mo)
▪ Males

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is different about the activity of ponatinib compared to other TKI

A

Ponatinib has activity in pts with T315I mutation which causes a structural change of the ATP binding pocket on BCR-ABL. This mutation causes resistance to all of the other TKIs.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

For each log reduction (1-5), list % the BCR-ABL transcript that is detectable. What is MMR, DMR and CMR?

A
Log 1=10% EMR
Log 2=1%
Log 3=0.1% MMR 
Log 4=0.01% DMR
Log 4.5=0.0032%
Log 5 = 0.001% CMR
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

In which CML patients would you consider transplant?

A
  1. Intolerant to all TKIs
  2. Blast phase (ideally get into CR with TKI or chemo)
  3. Patients relapsing with a T315I mutation because response to ponatinib is usually short.
  4. Accelerated phase with poor response to TKI
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is omacetaxine?

A

Protein synthesis inhibitor that has demonstrated activity in CML in chronic phase with a T315I mutation, or failure of 2 previous TKIs.

SC BID x 14days q28 days

SE: adverse events included hematological toxicity (thrombocytopenia, anemia, neutropenia, lymphopenia), gastrointestinal (diarrhea, nausea) toxicity, weakness and fatigue, as well as reaction at the injection site.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What are the 3 major break point mutations seen in CML?

A
  1. p190BCR-ABL1 (resulting from fusion at the minor breakpoint or m-BCR site)
  2. p210BCR-ABL1 gene product (resulting from fusion at the major breakpoint or M-BCR site)
  3. p230BCR-ABL1 (resulting from fusion at the micro breakpoint or mu-BCR site)

*p210 is most common.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is the median survival for blast phase CML? (in the TKI era)

A

bad! 7-11 months

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What is the criteria for complete hematological response (CHR) in CML?

A
  1. resolution of symptoms/signs of the disease, including palpable splenomegaly
  2. leukocytes <10 × 109/
  3. Normal differential (absence of immaturity (myelocytes, pro-myelocytes, blasts, etc.)
  4. platelets <450 × 109/L
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

How many Ph-positive metaphases are seen in: minor, minimal, major and complete cytogenetic response?

A
Based on marrow cyto:
complete (no Ph+ cells).
major (1 to 35 percent)
minor (36 to 65 percent)
minimal (66 to 95 percent) 
no response (>95 percent)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

5 unique toxicities of Nilotinib

A
  1. Hyperglycemia
  2. Hyperlipidemia
  3. Qtc prolongation
  4. Increased lipase
  5. Increased stroke risk
  6. increased CAD
  7. Increased PVD

*extreme caution in individuals with diabetes mellitus, cardiovascular disease, or metabolic syndrome

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

ENESTnd compared nilotinib (either 300mg or 400mg PO BID to Imantinib 400mg PO daily). What were the significant end points

A

Nilotinib was superior in terms of:

  1. EMR at 3 mos, CCyR at 12 months
  2. Time to progression to AP or blast phase
  3. MMR, MR
  4. Comparable PFS and OS (approximately 95 percent OS after two years) (300mg PO BID)

*Nilotinib 400 mg twice daily was superior to imatinib with regard to OS, PFS, EFS, and progression, but this dose was associated with unacceptable levels of CV toxicity.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Other that T315I, name 3 other markers of TKI resistance in CML.

A
  1. F317L
  2. F359V/C/I
  3. E255K/V
  4. V299L
  5. M244V
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Major side effects of potnatinib (BB warnings):

A
  1. Vascular events: MI, stroke, stenosis of large arterial vessels of the brain, severe PVD
  2. VTE
  3. Heart failure
  4. Hepatoxicity
    Others: HTN, rash, thrombocytopenia, abdominal pain.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What are the arguments for choosing 2nd generation TKI upfront for CP CML instead of imatinib?

A
  1. Quicker MMR and MR4.5
  2. Less mutation/resistance development
  3. Decreased rates of progression to AP, BP

But no change in PFS or OS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What is the single most important marker of OS and PFS for pts treated with TKI for CP CML?

A

Early molecular response, BCR-ABL transcripts =10%

*but failure to meet milestone is only a warning, as may be able to “catch up” if reach <1% @ 6 month milestone.

17
Q

When are 4 clinical situations where you might send mutational analysis for a pt with CML?

A
  1. BCR-ABL1 transcripts are >10% at 3 or 6 months or there is failure to meet other response milestones
  2. loss of cytogenetic or hematologic response occurs
  3. A 1-log or greater increase in BCR-ABL1 transcript levels together with a loss of MMR occurs
  4. Disease progression occurs.
18
Q

What are 3 factors with may lead to non-adherence to TKIs and 2 factors associated with good compliance?

A
  1. Male
  2. Older age
  3. Living alone
  4. High dose of TKi
  5. Longer length of TKI

Improved compliance:

  1. More education about CML
  2. Other comorbidites
  3. Taking other chronic meds
19
Q

A patient is eligible for TKI discontinuation. ~4 weeks after stopping their TKI they complain of arthralgias. What is this condition and what is the treatment?

A

“TKI withdrawal syndrome”
Occurs in 25% of pts who d/c TKIs within 1-6 weeks of stopping.
Looks like PMR- arthralgias of hips, shoulders, hands, and feet + pruritus
-Usually resolves spontaneously, but can persist for weeks to months.

20
Q

What was the DES-TINY study design for TKI discontinuation?

A

Looked at the benefit of an initial 12-month period of a 50% dose reduction from standard doses of imatinib, nilotinib, or dasatinib.

Eligibility: TKI x 3yrs, MMR (or MR 4.0 or deeper) x 12months

-After 1 year of dose reduction, recurrence was significantly lower in the MR4.0 cohort than in the MMR cohort.

21
Q

What is Omacetaxine mepesuccinate?

A

NOT a TKI (protein synthesis inhibitor) and therefore works through BCR-ABL-independent mechanism
– Approved for chronic or accelerated phase CML resistant and/or intolerant to 2+ TKIs
– AEs: myelosuppression, hyperglycemia

22
Q

Pt develops pleural effusion on Dasatinib 100mg PO daily, how will you manage?

A
  1. Hold Dasatanib
  2. CXR to confirm +/- Thora
  3. Supportive care such as diuretics
  4. If not improved x 7 days, add steroids
  5. Once resolved, can restart dasatanib at 80mg PO daily
23
Q

What is asciminib?

A

Asciminib is an allosteric inhibitor that binds a myristoyl site of the BCR-ABL1 protein, locking BCR-ABL1 into an inactive conformation through a mechanism distinct from those for all other ABL kinase inhibitors. Asciminib targets both native and mutated BCR-ABL1, including the gatekeeper T315I mutant.

NJEM 2019, worked in heavily pretreated pts including those that had failed ponatinib.

Does not bind the ATP binding domain as other TKis do.
s
SE: Pancreatitis, HA, fatigue, arthralgia

24
Q

What are 3 risk scores for CML?

A
  1. Sokal
  2. EUTOS
  3. Hasford
  4. ELTS
25
Q

What are the components of the Sokal score?

A
  1. Age
  2. Spleen size (below costal margin)
  3. Plt count
  4. Blast percentage
26
Q

How do you treat accelerated CML de-novo and progression?

A
  1. De novo- Start 2nd Gen TKI, if responding–>continue. If not responding, perform mutation analysis–>If T315I then switch to Ponatinib (or asciminib or omacetaxine)–> if still no response, refer for Tx.
  2. If progressed from chronic phase
    - perform T315i mutation analysis and switch TKI as above if present–>refer to Tx (even if responding).
    - If not Tx eligible, con’t on 2nd gen TKI or ponatinib until progression and then palliate.
27
Q

What is the defn of accelerated CML according to the WHO?

Taken out of WHO5
Now only chronic or blast
But RFs in CP matter like ACAs

A
  1. PB or BM blasts 10-19%
  2. PB basophils >/= 20%
  3. Plt<100, or >1000 (unrelated or unresponsive to therapy)
  4. Progressive splenomegaly or inc WBC, not responsive to therapy.
  5. Cytogenetic evolution or additional clonal chromosomal abnormalities in Ph+ cells @ diagnosis (trisomy 8 or 19, isochromosome 17q, 2nd Ph), complex karyotype or abnormalities of 3q26.2
28
Q

What are 4 common cytogenetic abnormalities found in CML (mostly in accelerated and blast phase) which confer poor prognosis?

A
  1. trisomy 8
  2. isochromosome 17q (leading to the loss of the P53 gene on 17p).
  3. trisomy 19
  4. duplication of the Ph chromosome
29
Q

How do you treat blast phase CML, initial diagnosis? (transplant eligible and transplant ineligible)

How do you treat blast phase CML, when pt previously on TKI?

A

All patients with blast crisis should undergo BCR-ABL1 kinase mutational analysis to aid in TKI selection

Diagnosed in blast phase

  1. Tx eligible- 2nd gen TKI–> transplant
  2. Tx ineligible–> TKI

Progression to blast phase from accelerated phase or chronic phase?
1. Administer AML-type induction chemotherapy combined with a more potent TKI for remission induction.

Patients with CML in LYMPHOID blast crisis are treated with combination chemotherapy in addition to a BCR-ABL1 TK